



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

## ***Table of Contents and List of Tables***

Copyright VENTURE PLANNING GROUP  
This material is confidential for use by our clients only  
and may not be reprinted or reproduced.

VPG Publications, Consulting, Clients ***www.VPGcorp.com***

VPG Market Research Reports ***www.VPGMarketResearch.com***

Partner Reports ***www.LeadingMarketResearch.com***

**VENTURE PLANNING GROUP** 1271 Avenue of the Americas, Suite 4300 New York, NY 10020  
Phone + 1 212 564 2838 Fax + 1 212 564 8133 ***reports@vpgcorp.com***

## Table of Contents

### Introduction

### Worldwide Market and Technology Overview

#### A. Cancer Statistics and Etiology

1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer

#### B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin

Table of Contents (continued)

16. *NSE*
17. *Occult Blood*
18. *PAP Smear/HPV*
19. *Prostatic Acid Phosphatase (PAP)*
20. *Prostate-Specific Antigen (PSA)*
21. *Squamous Cell Carcinoma Antigen (SCC)*
22. *T and B Lymphocytes*
23. *TdT*
24. *Thyroglobulin*
25. *Tissue Polypeptide Antigen (TPA)*
26. *Biochemical Tumor Markers*
  - *ADA*
  - *B-Protein*
  - *PNP*
  - *5'-Nucleotidase*
27. *Oncogenes*
  - *Abl/abl-bcr*
  - *AIB1*
  - *BCL-2*
  - *BRCA1*
  - *CD44*
  - *C-fos*
  - *C-myb*
  - *C-myc*
  - *CYP-17*
  - *Erb-B*
  - *HPC1*
  - *N-myc*
  - *P40*
  - *P51*
  - *P53*
  - *PIK3CA*
  - *PTI-1*
  - *Ras*
  - *Reg*
  - *Sis*
  - *Src*

Table of Contents (continued)

28. *Polypeptide Growth Factors*

- *Basic Fibroblast Growth Factor*
- *Beta-TGF*
- *Cachectin (TNT)*
- *Calmodulin*
- *ECFR*
- *Nerve Growth Factor (NGF)*
- *Epidermal Growth Factor (EGF)*
- *Ornithine Decarboxylase*
- *Transferrin*
- *Transforming Growth Factor-Alpha*

29. *Ectopic Hormones*

30. *Colony Stimulating Factors*

31. *Lymphokines*

- *Alpha-Interferon*
- *B Cell Growth Factors*
- *B Cell Growth Factor (BCGF)*
- *Gamma-Interferon*
- *Interleukin-1 (IL-1)*
- *Macrophage Activating Factor*

32. *Immunohistochemical Stains*

33. *Emerging Tumor Markers*

- *N-Acetylglucosamine*
- *Actin*
- *Alpha-Actin*
- *Antineuronal Antibodies*
- *7B2*
- *B72.3*
- *Bax*
- *BCD-F9*
- *BLCA-4*
- *Blood Group Antigens A,B,H*
- *CA 50*
- *CA 72-4/TAG-72*
- *CA 195*
- *CA-242*
- *CA-549*
- *CAM 26*
- *CAR-3*

Table of Contents (continued)

- *Cathepsin-D*
- *Chromogranin A and B*
- *Cluster 1 Antigen*
- *Cluster-5/5A Antigen*
- *CTA*
- *CU18*
- *DR-70*
- *DU-PAN-2*
- *Endometrial Bleeding Associated Factor*
- *Endostatin*
- *Epithelial Membrane Antigen*
- *Feulgen Hydrolysis*
- *Fibronectin*
- *FSH*
- *(1->3)-L-fucosyltransferase*
- *Gastrin-Releasing Peptide (GRP)*
- *GDCFP-15*
- *Glucagon*
- *Glycoamines*
- *H23*
- *Her-2*
- *Human Carcinoma Antigen*
- *HPA*
- *HSP27*
- *Intermediate Filaments*
  - *Cytokeratins/CK18/Cyfra 21-1*
  - *Desmin*
  - *Gliofibrillary Acid Protein*
  - *Neurofilaments*
  - *Vimentin*
- *KA 93*
- *Kinases*
- *KP16D3*
- *LAI*
- *Leukocyte Common Antigen*
- *Lewis Antigens*
- *Lysophosphatidic Acid (LPA)*
- *Ma 695/Ma 552*
- *MABDF3*
- *MAG*
- *ME1*

Table of Contents (continued)

- *Minactivin*
- *MN/CA9*
- *MSA*
- *Mucin Cancer Antigen (MCA)*
- *Multiple Tumor Suppressor 1*
- *Myosin*
- *NEA-130*
- *NMP22*
- *OA-519*
- *Opiod Peptides*
- *P-glycoprotein*
- *Pancreatic Oncofetal Antigen (POA)*
- *Placental Lactogen*
- *PR92*
- *Proliferative Index, Ki-67*
- *Px*
- *RB Inactivation/Deletion*
- *Ret*
- *SCCL 175*
- *Selectin*
- *Sialic Acid*
- *Sialyl SSEA-1/SLX*
- *SN10*
- *Somatostatin*
- *TA-90*
- *TABA*
- *Tachykinin*
- *TAG 12*
- *TPS*
- *Troponin*
- *Tubulin*
- *VCAM*
- *VEGF*
- *Villen*

**C. Instrumentation Review And  
Market Needs**

1. *Abbott AxSYM*
2. *Abbott Architect c4000*
3. *Abbott Architect i2000 Series*
4. *Abbott Architect ci8200 System*

Table of Contents (continued)

5. Beckman Coulter UniCel Series
  6. Beckman Coulter Access
  7. Binding Site ESP600
  8. bioMerieux Mini Vidas
  9. Carolina Chemistries BioLis 24i
  10. DiaSorin Liaison
  11. Horiba ABX Pentra 400
  12. Inverness DS2
  13. J&J Vitros ECi/ECiQ
  14. J&J Vitros 3600
  15. J&J Vitros 5600
  16. Olympus AU5400
  17. Olympus AU3000i
  18. Olympus AU2700
  19. Roche Modular Analytics
  20. Roche Cobas Integra 400
  21. Roche Cobas Integra 400 Plus
  22. Roche Elecsys
  23. Roche Cobas c311
  24. Siemens ADVIA Centaur
  25. Siemens Dimension
  26. Siemens Dimension RxL Max
  27. Siemens Dimension Vista 500
  28. Siemens Immulite
  29. Siemens Stratus
  30. Tosoh AIA-Series
  31. Vital Diagnostics ATAC 8000
  32. Vital Diagnostics Envoy 500
- D. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    - a. Technological Principle
    - b. Radioimmunoassay (RIA)
    - c. Enzyme Immunoassays (EIA)
      - Overview
      - ELISA
      - Immunofiltration
      - Particle-Membrane Capture Immunoassay
      - Enzyme Amplification

Table of Contents (continued)

- d. *Fluorescent Immunoassays*
- e. *Luminescence*
  - *Chemiluminescence*
  - *Bioluminescence*
- f. *Latex Agglutination*
- g. *Immunoprecipitation*
- H. *Affinity Chromatographu*
- e. *Liposome Flow-Injection Immunoassay*
- 3. *Molecular Diagnostics*
  - a. *Technology Overview*
  - b. *Amplification Methods*
    - *PCR*
      - *DAP-PCR*
      - *Immuno-PCR*
      - *QC-PCR*
    - *CAR*
    - *DNA*
    - *HPA*
    - *LCR*
    - *NASBA*
    - *QBR*
    - *SDA*
    - *3 SR, and others*
- 4. *Chromosome Analysis*
  - a. *Chronic Myelogenous Leukemia (CML)*
  - b. *Acute Myeloid Leukemia (AML)*
  - c. *Acute Lymphoblastic Leukemia (ALL)*
  - d. *Malignant Lymphomas*
    - Lymphoid Malignancies*
  - e. *Chronic Lymphocytic Leukemia (CLL)*
  - f. *Solid Cancers*
  - g. *Chromosomal Translocation and Oncogenes*
- 5. *Artificial Intelligence*
- 6. *Flow Cytometry*
- 7. *Two Dimensional Gel Electrophoresis (2-DGE)*
- 8. *Biosensors*
- 9. *Competing/Complementing Technologies*
  - a. *CT*
  - b. *MRI*



Table of Contents (continued)

- c. NMR
- d. PET
- e. Photonics Spectroscopy
- E. Personal Testing

Japan

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types of Distributors
  - 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition

Table of Contents (continued)

*D. Technological Edge and Limitations*

*E. Patent Protection*

*F. Regulatory Constraints*

*G. Decentralized Testing Market Challenges*

Competitive Profiles

- *Abbott*
- *AdnaGen/Alere*
- *Agilent Technologies*
- *Applied Gene Technologies*
- *Arca Biopharma*
- *Beckman Coulter/Danaher*
- *Becton Dickinson*
- *Biomedical Diagnostics*
- *bioMerieux*
- *Bio-Rad*
- *CellSearch*
- *Cepheid*
- *Correlogic Systems/Vermillion*
- *Decode Genetics*
- *Diadexus*
- *Diagnocure*
- *Diasorin*
- *Eiken Chemical*
- *Elitech Group*
- *Enterix*
- *Enzo Biochem*
- *Epigenomics*
- *Exact Sciences*
- *Fujirebio*
- *Guided Therapeutics*
- *Hologic/Gen-Probe*
- *Kreatech/Leica*
- *Kyowa Medex*
- *Mackay Life Sciences*
- *Myriad Genetics*

Table of Contents (continued)

- OncoLab
- Otho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

Appendixes

- Appendix I: Major Universities and Research  
Centers Developing Cancer Diagnostic  
Technology and Applications
- Appendix II: Assumed Currency Exchange Rates

List of Tables

*Tumor Marker Classification*

*Major Companies Developing or Marketing  
ACTH Tests*

*Major Companies Developing or Marketing  
AFP Tests*

*Major Companies Developing or Marketing  
Beta-2 Microglobulin Tests*

*Major Companies Developing or Marketing  
CA 15-3/27.29 Tests*

*Major Companies Developing or Marketing  
CA 19-9 Tests*

*Major Companies Developing or Marketing  
CA 125 Tests*

*Major Companies Developing or Marketing  
Calcitonin Tests*

*Major Companies Developing or Marketing  
CEA Tests*

*Major Companies Developing or Marketing  
Estrogen Receptor Tests*

*Major Companies Developing or Marketing  
Progesterone Receptor Tests*

*Major Companies Developing or Marketing  
Ferritin Tests*

*Major Companies Developing or Marketing  
Gastrin Tests*

List of Tables (continued)

*Major Companies Developing or Marketing  
HCG Tests*

*Major Companies Developing or Marketing  
Insulin Tests*

*Major Companies Developing or Marketing  
NSE Tests*

*Major Companies Developing or Marketing  
Occult Blood Tests*

*Major Companies Developing or Marketing  
PAP Smear/HPV Tests*

*Major Companies Developing or Marketing  
PAP Tests*

*Major Companies Developing or Marketing  
PSA Tests*

*Major Companies Developing or Marketing  
Lymphocyte Subclassification Tests*

*Biochemical Markers Potential Applications  
In Cancer Diagnosis*

*Oncogenes Potential Applications  
In Cancer Diagnosis*

*Major Companies Developing or Marketing  
Oncogene Tests*

*Growth Factors Potential Applications  
In Cancer Diagnosis*

*Colony Stimulating Factors Potential  
Applications in Cancer Diagnosis*

*Lymphokines Potential Applications  
In Cancer Diagnosis*

List of Tables (continued)

*Immunohistochemical Stains Potential  
Applications in Cancer Diagnosis*

*Executive Summary Table: Japan, Hospital  
Cancer Diagnostic Test Volume and Sales Forecast*

*Japan, Estimated Cancer Death Rates  
Per 100,000 Population*

*Japan, Hospital Laboratories Performing  
Cancer Diagnostic Tests*

*Japan, Hospital Laboratories Performing  
Cancer Diagnostic Tests by Bed Size*

*Japan, Hospital Laboratories Major  
Cancer Diagnostic Test Volume Forecast by Test*

*Japan, Hospital Laboratories Cancer Diagnostic  
Sales Forecast by Test*

*Japan, Total Cancer Diagnostics  
Sales by Major Supplier*

*Japan, AFP Testing Market Diagnostics  
Sales by Major Supplier*

*Japan, CA 15-3/27.29 Testing Market  
Diagnostics Sales by Major Supplier*

*Japan, CA 19-9 Testing Market Diagnostics  
Sales by Major Supplier*

*Japan, CA 125 Testing Market Diagnostics  
Sales by Major Supplier*

*Japan, Calcitonin Testing Market Diagnostics  
Sales by Major Supplier*

List of Tables (continued)

*Japan, PAP Testing Market Diagnostics  
Sales by Major Supplier*

*Japan, PSA Testing Market Diagnostics  
Sales by Major Supplier*